Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:


Guest: Welcome to ChinaBio
® Today!

As a guest to ChinaBio® Today, you have access to summaries of over 3000 articles including our archives.  You can use the Search feature on the left menu bar to find what you're looking for, or you can browse summaries of our articles by the categories listed under Subscriber Articles. You can access any article that is marked as FREE. Or you can subscribe and have access to our entire content.   

Top Stories

>> See all top stories...

Recent Articles

Recent Articles

  Week in Review: BioSense Signs $68 Million China Deal with Neovacs For Therapeutic Vaccine (in: Week in Review)
  Xynomic Pharma In-Licenses Global Rights to HDAC Inhibitor for Cancer (in: Deals & Financings)
  Fudan-Zhangjiang Bio-Pharma Invests $2 Million in Adgero of the US (in: Deals & Financings)
  Qilu Pharma Launches Biosimilar to AstraZeneca's Iressa in China (in: News & Analysis)
  Anxin Doctor, a Mobile Health App, Announces $28 Million Funding (in: Deals & Financings)
  BioSense Inks $68 Million Deal for Neovacs’ Autoimmune Disease Vaccine in China (in: Deals & Financings)
  Hong Kong's Ally Bridge Invests in Two European Biopharmas (in: Deals & Financings)
  Lee's Pharm to Market Solasia's Oral Mucositis Treatment in China (in: Deals & Financings)
  Hutchison MediTech Begins Phase II Study of Its PSC Drug Savolitinib in China (in: Trials & Approvals)
  Eisai to Market Orion’s Two Parkinson’s Disease Drugs in China (in: Deals & Financings)